Ipafricept
Based on 4 publication(s) in Google Scholar
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.80%
- No. CAS: 1391727-24-4
- Peso molecular:81.97 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ipafricept
More
Actividad biológica
Wnt ligand[1]
Ipafricept (10 μg/mL, 4 h) inhibits the pro-proliferative and and migration effects of peptide RL-QN15 on human embryonic stem cells (hESCs) [3].
Ipafricept (10 μg/mL, 0-48 h) reverses the RL-QN15-induced activation of the Wnt/β-catenin signaling pathway, leading to the reversal of the effects of RL-QN15 on the proliferation, migration and stemness of hESCs[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human embryonic stem cells
-
Concentration:10 μg/mL
-
Incubation Time:4 h
-
Result:Markedly reduced the RL-QN15-induced increase in TCF7L1, TCF7L2 levels and stemness of hESCs, as well as CK19 protein levels in hESCs.
Ipafricept (45 mg/kg every 2 weeks, i.p., for 42 days) results in greater antitumor activity of WNT blockade and tumor growth inhibition in combination with Nab-paclitaxel (HY-P99974) (7.5 mg/kg every week) than Carboplatin (HY-17393) (30 mg/kg every week) in ovarian cancer xenograft mouse models[2].
Ipafricept (10 mg/kg, s.c., administered on day 0 and 3) competes with RL-QN15 for binding, reducing the interaction of RL-QN15 with FZD8, thereby counteracting its activation of the Wnt/β-catenin signaling pathway in mouse full-thickness skin injury models[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pancreatic cancer xenograft mouse models[2]
-
Dosage:10 mg/kg weekly or 25 mg/kg every 2 weeks
-
Administration:i.p., weekly or every 2 weeks for 42 days
-
Result:Markedly increased the antitumor activity in combination with Gemcitabine (HY-17026) and Nab-paclitaxel (HY-P99974) in pancreatic cancer xenograft mouse models.
-
Animal Model:Ovarian cancer xenograft mouse models[2]
-
Dosage:45 mg/kg every 2 weeks
-
Administration:i.p., every 2 weeks for 42 days
-
Result:Resulted in greater tumor growth inhibition in combination with Nab-paclitaxel (HY-P99974) than Carboplatin (HY-17393) in ovarian cancer xenograft mouse models.
-
Animal Model:Mouse full-thickness skin injury models[3]
-
Dosage:10 mg/kg
-
Administration:s.c., administered on day 0 and 3
-
Result:Decreased the skin wound healing rate to less than 60% combined with RL-QN15 and inhibited RL-QN15-induced re-epithelialization in mouse full-thickness skin injury models.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
[FZD8 (frizzled class receptor 8, frizzled family receptor 8, Frizzled-8)]2-IGHG1 Fc (Fragment constant)
ELISA, FACS, Functional assay
Chemical Information
-
No. CAS 1391727-24-4
-
Appearance Liquid
-
Peso molecular 81.97 kDa
-
Color Colorless to light yellow
-
SMILES
[Ipafricept]
-
Synonyms
OMP-54F28; FZD8-Fc
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Nat Biotechnol
Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma. [Abstract]2026 Jan 5. PMID: 41491256 -
-
-
Pureza y Documentación
-
Ficha de datos (266 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Jimeno A, et al. A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Dec 15;23(24):7490-7497. [Content Brief]
[2]. Fischer MM, et al. WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Sci Adv. 2017 Jun 21;3(6):e1700090. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz